BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Philosys Anticipates FDA Approval for New Gmate® Blood Glucose Monitoring System


8/3/2012 8:01:33 AM

NEW YORK, Aug. 2, 2012 /PRNewswire/ -- Philosys announced today that it has applied for approval from the U.S. Food and Drug Administration (FDA) for its Gmate® blood glucose monitoring system in Q4 2011, and expects approval in third quarter 2012. The new Gmate® SMART is the smallest and most innovative meter in the world. It's Smartphone technology is patent pending, and is the world's only blood glucose meter to work with the headphone connector of the iPhone, iPad, and iPod.

"We are very excited to be close to FDA approval for our blood glucose monitoring technology and are preparing to bring this capability to the United States," said Jennifer Kupar, Operations Manager for Philosys. Gmate® SMART is the world's first "True Smartphone Meter." Given the dramatic rise of diabetes in the US and more tech savvy consumers, there is a growing demand for this medical technology that Philosys can meet."

Diabetic technology in the U.S. has not kept pace with the digital explosion of smartphones, tablets, and other digital devises. The US Centers for Disease Control predicts that as many as 1 in 3 U.S. adults could have diabetes by 2050. This increase could bring the average incidence of diabetes to more than 30 percent of the population.

"More and more U.S. consumers with diabetes are purchasing Smartphones daily," Kupar continued. "Gmate® is the perfect solution for diabetics seeking digital solutions to monitor their disease with the push of a button. We look forward to FDA approval of our revolutionary device this year."

About GmateTM
The GmateTM blood glucose monitoring system is diabetic technology that makes life simple for consumers. GmateTM SMART is the smallest and most innovative meter in the world and works with the iPhone. For more information, visit http://www.gmate.com or Jennifer Kupar at jkupar@gmate.com.

About Philosys
Philosys is a manufacturing company that specializes in medical, diagnostic and analytical instruments. The range of services provided covers the entire product cycle from concept through to manufacture. Philosys's philosophy is to develop cost-effective design and manufacturing solutions that satisfy our customer's vision. http://www.gmate.com

SOURCE Philosys, Inc.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->